



This material is not intended for general distribution in the United States, Canada, Japan, Hong Kong, New Zealand, South Africa or Australia or in any state or jurisdiction where distribution would be unlawful

KB COMPONENTS – TERM SHEET

Issuer	KB Components AB ("KB Components" or the "Company")
Offering Type	Initial Public Offering ("IPO")
Listing Venue	Nasdaq First North Premier Growth Market
Ticker / ISIN	KBC SS / SE0022725743
Offering Structure	Base offering: 14,608,696 existing shares / Approx. SEK 555 million / Approx. USD 51 million Over-allotment option: Corresponding of up to 15% of the Base offering Total offering: up to 16,800,000 existing shares / Approx. SEK 638 million / Approx. USD 58 million
Offer price	SEK 38 per share
Shares outstanding	56,000,000 shares
Implied market cap	Approximately SEK 2.1 billion / USD 194 million
Selling shareholders	BrA Invest CKS AB (the "Principal Shareholder"): 11,108,696 shares and over-allotment option of up to 15% of the Base offering Lars Holtskog AB: 2,800,000 shares Deebrade AB: 700,000 shares
Current ownership structure	BrA Invest CKS AB (the "Principal Shareholder"): 52,500,000 shares Lars Holtskog AB: 2,800,000 shares Deebrade AB: 700,000 shares
Lock-up	The Principal Shareholder has agreed, subject to certain exceptions, not to sell its holdings of shares in the Company or take certain other actions in respect of its holdings and, where applicable, other securities for a period of 360 days from the first day of trading of the Company's shares on Nasdaq First North Premier
Business description	KB Components was founded in 1947 and has since developed into a global player in advanced polymer component manufacturing with production facilities in Europe, North and Central America, and Asia. Through a global presence, deep expertise in injection molding technology, and well-invested machinery with a high degree of automation, the Company delivers polymer components to more than 1,000 customers across a wide range of application areas, including heavy and light vehicles, medical technology, and general industry. The Company is headquartered in Örkelljunga and had approximately 1,500 employees as of 30 September 2024
Reason for listing	The Company's board of directors and main shareholder, with the support of the management team, have made the assessment that the Listing and the Offering are a natural next step in the Company's development. The Listing will increase the awareness of KB Components operations and strengthen the KB Components' profile and brand towards investors, partners, and customers. The Listing will also give the Company access to the Swedish and international capital markets and expand the shareholder base. The Board of Directors aim to, depending on market conditions, list the Company's shares on Nasdaq Stockholm's main list within 12 months after the Listing on Nasdaq First North Premier is completed
Timetable	2 December 2024: Publication of the prospectus 3 December – I December 2024: Application period for the general public in Sweden 3 December – I December 2024: Application period for institutional investors I I December 2024: First day of trading I 3 December 2024: Settlement date (DVP T+2)
Documentation	Prospectus in Swedish available on the Company's website. English translation for institutional investors available upon request
Selling restrictions	The shares will be offered to institutional investors in Sweden and internationally, and to the general public in Sweden International offering to institutions outside the U.S. in compliance with Reg S End target market for the shares is professional investors and retail as well as eligible counterparties which do not need a guaranteed income or capital protection
Carnegie Research	IPO research published on 20 November 2024 Carnegie clients will receive electronic copies of Carnegie's research report through ResearchFN – please check your inbox for emails from CarnegielPOresearch@mg.researchfn.com The blackout period begins 23:59 (CET) on 20 November – no distribution of research after this time
Carnegie Analysts	Mikael Laséen / mikael.laseen@carnegie.se / +46 8 5886 87 2 I Jakob Söderblom / jaksod@carnegie.se / +46 8 5886 86 43 Anna Widström / anna.widstrom@carnegie.se / +46 8 5886 85 34 Henrik Christiansson / henrik.christiansson@carnegie.se / +46 8 5886 85 03
Syndicate	Handelsbanken is Sole Global Coordinator and Joint Bookrunner Carnegie is Joint Bookrunner

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

In Sweden the material is produced by Carnegie Investment Bank AB (publ) ("Carnegie"). Carnegie is under the supervision of the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland the material is produced by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finansisvalvonta). In Denmark the material is produced by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finansilsynet). In Norway the material is produced by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finansilsynet).

The material is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction. While all reasonable care has been taken to ensure that the information in this material is true and not misleading, Carnegie does not guarantee its accuracy or completeness. This information is subject to change.